Nyrada Inc (#ASX: $NYR) announced that Nyrada PCSK9 inhibitor (NYX-PCSK9i) demonstrates equivalency to the two FDA approved monoclonal PCSK9 antibodies, Repatha® and Praluent®, in healthy human white blood cells. https://t.co/qeNuHc9tII. #Pharmaceutical #drugs #stocks #Investment https://t.co/RcHGEil7sC